Latest Conference Articles

May 3rd 2018, 9:30pm

ASPHO Conference

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses key molecular pathways in pediatric bone sarcoma.

May 3rd 2018, 9:29pm

ASPHO Conference

Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the utilization of liquid biopsies in pediatric patients with sarcoma.

May 3rd 2018, 3:06am

ASPHO Conference

CAR T-cell therapy can induce next generation sequencing negativity in patients with relapsed/refractory acute lymphoblastic leukemia, suggesting a "synergistic" relationship with hematopoietic cell transplant.

April 19th 2018, 7:27pm

AACR Annual Meeting

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the updated findings from the CheckMate-141 trial in head and neck cancer.

April 19th 2018, 7:24pm

AACR Annual Meeting

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a basket study of taselisib in patients with PIK3CA-mutated solid tumors.

April 18th 2018, 9:28pm

AACR Annual Meeting

A search for molecular guidance in the use of anti-PD-1 therapy in urothelial cancer pointed toward myeloid-derived suppressor cells as a potentially useful biomarker.

April 18th 2018, 1:36am

AACR Annual Meeting

Tumor mutational burden in non–small cell lung cancer identified patients who were more likely to respond to first-line combination immunotherapy with nivolumab and ipilimumab, an updated analysis of CheckMate-586 clinical trial data showed.

April 18th 2018, 1:35am

AACR Annual Meeting

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the efficacy of lorlatinib in ALK-positive non–small cell lung cancer.

April 18th 2018, 1:33am

AACR Annual Meeting

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of adjuvant anti–PD-L1 agents on the treatment landscape of melanoma.

April 17th 2018, 11:37pm

AACR Annual Meeting

Treatment with nivolumab reduced the risk of death by 32% compared with investigator’s choice of therapy for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

April 17th 2018, 9:21pm

AACR Annual Meeting

Combination use of CMP-001, an intratumoral toll-like receptor 9 agonist, and pembrolizumab (Keytruda) showed clinical activity in reversing PD-1 checkpoint inhibition resistance in patients with metastatic melanoma.

April 17th 2018, 8:07pm

AACR Annual Meeting

Adding atezolizumab to chemotherapy and an angiogenesis inhibitor led to significant improvement in progression-free survival for patients with untreated advanced nonsquamous non-small cell lung cancer.

April 17th 2018, 3:30pm

AACR Annual Meeting

Adding the IDO1 inhibitor epacadostat to the PD-L1 inhibitor durvalumab (Imfinzi) failed to induce any clinical responses in patients with pancreatic cancer.

April 17th 2018, 12:57am

AACR Annual Meeting

Padmanee Sharma, MD, PhD, scientific director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, discusses updated findings from the CheckMate-275 trial in bladder cancer during an interview at the 2018 AACR Annual Meeting.

April 17th 2018, 12:55am

AACR Annual Meeting

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the results of a study investigating durvalumab (Imfinzi) plus tremelimumab in patients with metastatic urothelial cancer.

April 17th 2018, 12:43am

AACR Annual Meeting

The combination of nivolumab and ipilimumab more than tripled the 1-year progression-free survival rate versus chemotherapy for treatment-naïve patients with non–small cell lung cancer with high tumor mutation burden.

April 16th 2018, 10:47pm

AACR Annual Meeting

Neoadjuvant treatment with nivolumab demonstrated a 45% major pathologic response rate in patients with resectable stage I to III non–small cell lung cancer irrespective of PD-L1 expression.

April 16th 2018, 10:39pm

European Lung Cancer Congress

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the significance of the phase III results of the FLAURA trial, which explored osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutant non

April 16th 2018, 10:16pm

AACR Annual Meeting

An off-the-shelf, dual-targeted chimeric antigen receptor T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.

April 16th 2018, 9:56pm

AACR Annual Meeting

Combining pembrolizumab (Keytruda) with standard chemotherapy in the frontline setting reduced the risk of death by over 50% in patients with nonsquamous non–small cell lung cancer without EGFR or ALK mutations.